

Matthew S Waitkus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5801690/publications.pdf>

Version: 2024-02-01

24
papers

955
citations

759233

12
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

2137
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological Role and Therapeutic Potential of IDH Mutations in Cancer. <i>Cancer Cell</i> , 2018, 34, 186-195.	16.8	234
2	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 16-26.	1.2	221
3	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.	12.8	124
4	The integrated genomic and epigenomic landscape of brainstem glioma. <i>Nature Communications</i> , 2020, 11, 3077.	12.8	50
5	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. <i>Cancer Research</i> , 2017, 77, 6097-6108.	0.9	46
6	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. <i>Molecular Cancer Research</i> , 2017, 15, 507-520.	3.4	41
7	Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform. <i>Molecular and Cellular Biology</i> , 2014, 34, 1800-1811.	2.3	35
8	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. <i>Cancer Research</i> , 2018, 78, 36-50.	0.9	35
9	Sensitive and rapid detection of <i>TERT</i> promoter and <i>IDH</i> mutations in diffuse gliomas. <i>Neuro-Oncology</i> , 2019, 21, 440-450.	1.2	27
10	Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. <i>Nanotechnology</i> , 2019, 30, 275101.	2.6	21
11	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. <i>Molecular Cancer Research</i> , 2020, 18, 968-980.	3.4	18
12	Mitogen-Activated Protein Kinase Phosphatase-1 Promotes Neovascularization and Angiogenic Gene Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1020-1031.	2.4	15
13	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. <i>Molecular Cancer Research</i> , 2019, 17, 2042-2050.	3.4	15
14	Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. <i>Clinical Cancer Research</i> , 2021, 27, 383-388.	7.0	12
15	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 2180-2195.	7.0	12
16	Synergistic Induction of Mitogen-Activated Protein Kinase Phosphatase-1 by Thrombin and Epidermal Growth Factor Requires Vascular Endothelial Growth Factor Receptor-2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1983-1989.	2.4	11
17	STAT3-mediated Coincidence Detection Regulates Noncanonical Immediate Early Gene Induction. <i>Journal of Biological Chemistry</i> , 2013, 288, 11988-12003.	3.4	11
18	A Modified Nucleoside 6-Thio-2-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 6800-6814.	7.0	10

#	ARTICLE	IF	CITATIONS
19	TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. <i>Acta Neuropathologica Communications</i> , 2021, 9, 178.	5.2	8
20	Release of Nonmuscle Myosin II from the Cytosolic Domain of Tumor Necrosis Factor Receptor 2 Is Required for Target Gene Expression. <i>Science Signaling</i> , 2013, 6, ra60.	3.6	6
21	Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome. <i>Familial Cancer</i> , 2019, 18, 261-265.	1.9	3
22	GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi112-vi112.	1.2	0
23	TMOD-33. ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi275-vi275.	1.2	0
24	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi103.	1.2	0